两年前，一位联邦法官批准了一项由美国司法部介入，广为人知的检举诉讼案。指控Wyeth公司非法营销未经批准的Rapamune肾移植药物用于非洲裔美国人。如今，辉瑞制药公司（Pfizer）在2009年收购了Wyeth公司，并拨款4.91亿美元获取联邦批准。
 

Pfizer Inc. (PFE) Sets Aside $491 Million for Rapamune Marketing

11/2/2012 6:49:33 AM

Two years ago, a federal judge approved a move by the US Justice Department to intervene – or join – a widely publicized whistleblower lawsuit that accused Wyeth of illegally marketing the Rapamune kidney transplant drug for unapproved uses and for targeting African-Americans, a high-risk patient group. Now, Pfizer – which bought Wyeth in 2009 – has set aside $491 million in connection with an agreement-in-principle with the feds (see this).

There have been many off-label allegations, but this particular lawsuit prompted considerable interest because of the sensational accusation that Wyeth targeted African-Americans. Wyeth managers were allegedly aware of limited data for Rapamune use in high-risk patients, but Wyeth deliberately targeted two hospitals with mostly African-American patients – Philadelphia’s Einstein Medical Center and New York’s SUNY Downstate Medical Center.